Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 8.92
- Piotroski Score 5.00
- Grade Buy
- Symbol (LLY)
- Company Eli Lilly and Company
- Price $786.36
- Changes Percentage (-3.14%)
- Change -$25.45
- Day Low $783.51
- Day High $809.19
- Year High $972.53
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- Last Earnings 10/28/2024
- Ex-Dividend for 5/16 Dividend 11/15/2024
- Dividend Payable 12/10/2024
- Today N/A
- Next Earnings (Estimated) 02/03/2025
- Fiscal Year End N/A
- Average Stock Price Target $899.00
- High Stock Price Target $1,150.00
- Low Stock Price Target $300.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $6.78
- Trailing P/E Ratio 125.37
- Forward P/E Ratio 125.37
- P/E Growth 125.37
- Net Income $5.24 B
Income Statement
Quarterly
Annual
Latest News of LLY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
I sat in court the day an infamous cold murder case finally broke open
As a young reporter in Long Island, the author covered the trial of Rudolph Hoff, a man accused of a decades-old murder. Hoff's ex-wife's testimony led to his conviction....
By Newsweek | 17 hours ago -
College football Week 12 oddly specific predictions: BYU finally falls, Georgia rebounds
The writer reflects on their recent picks, focusing on key college football games. They share insights and predictions for upcoming matchups, highlighting players and teams to watch. Despite some miss...
By The New York Times | 17 hours ago -
Russian TV hosts fawn over Donald Trump's cabinet picks -- "Totally wonderful"
Russian TV hosts praised President-elect Donald Trump's cabinet picks as "totally wonderful." They discussed the selections' impact on the war in Ukraine. However, not all social media reactions were ...
By Newsweek | 17 hours ago
